{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-193940","form_type":"8-K/A","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.895040+00:00","generated_at":"2026-05-15T01:02:08.963183+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pyxis Oncology enters CEO separation agreement: 18-mo salary, equity acceleration, board resignation","bullets":["Separation Agreement with former CEO Lara Sullivan became binding April 29, 2026; she resigned from Board same day.","Dr. Sullivan will receive current salary for 18 months and health coverage for up to 12 months.","All unvested RSUs and stock options accelerated; option exercise period extended to December 31, 2030.","One-year post-separation non-solicitation and mutual non-disparagement covenants apply."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-193940","json":"https://secwatch.observer/filing/0001193125-26-193940.json","markdown":"https://secwatch.observer/filing/0001193125-26-193940.md","text":"https://secwatch.observer/filing/0001193125-26-193940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/0001193125-26-193940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/pyxs-20260206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:02:08.963183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ab73f3ab6","claim":"Lara Sullivan resigned as Director at Pyxis Oncology, Inc..","evidence_excerpt":"Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/0001193125-26-193940-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b4e5b0baaf","claim":"Lara Sullivan departed as Chief Executive Officer at Pyxis Oncology, Inc..","evidence_excerpt":"On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/0001193125-26-193940-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}